| Title |
The role of taxanes in triple-negative breast cancer: literature review
|
|---|---|
| Published in |
Drug Design, Development and Therapy, August 2015
|
| DOI | 10.2147/dddt.s86105 |
| Pubmed ID | |
| Authors |
Giorgio Mustacchi, Michelino De Laurentiis |
| Abstract |
Breast cancer (BC) is the most frequent tumor worldwide. Triple-negative BCs are characterized by the negative estrogen and progesterone receptors and negative HER2, and represent 15% of all BCs. In this review, data on the use of taxanes in triple-negative BCs are analyzed, concluding they are effective in any clinical setting (neoadjuvant, adjuvant, and metastatic). Further, the role of nab-paclitaxel (formulation of albumin-bound paclitaxel) in these tumors is also evaluated. The available data show the clinical potential of nab-paclitaxel based combinations in terms of long-duration response, increased survival, and better quality of life of patients with triple-negative metastatic BC. The ongoing trials will give further information on the better management of this type of tumor. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 138 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | <1% |
| Unknown | 137 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 23 | 17% |
| Student > Ph. D. Student | 21 | 15% |
| Researcher | 13 | 9% |
| Student > Postgraduate | 12 | 9% |
| Student > Bachelor | 10 | 7% |
| Other | 19 | 14% |
| Unknown | 40 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 23% |
| Biochemistry, Genetics and Molecular Biology | 27 | 20% |
| Pharmacology, Toxicology and Pharmaceutical Science | 12 | 9% |
| Agricultural and Biological Sciences | 10 | 7% |
| Chemistry | 6 | 4% |
| Other | 9 | 7% |
| Unknown | 42 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 March 2018.
All research outputs
#7,278,043
of 25,584,565 outputs
Outputs from Drug Design, Development and Therapy
#472
of 2,254 outputs
Outputs of similar age
#77,817
of 276,761 outputs
Outputs of similar age from Drug Design, Development and Therapy
#28
of 148 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 2,254 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 276,761 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 148 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.